You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHexobarbital
Accession NumberDB01355  (EXPT03301)
TypeSmall Molecule
GroupsApproved
DescriptionA barbiturate that is effective as a hypnotic and sedative. [PubChem]
Structure
Thumb
Synonyms
5-(1-Cyclohexen-1-yl)-1,5-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione
5-(1-cyclohexen-1-yl)-1,5-dimethylbarbituric acid
5-Cyclohex-1-enyl-1,5-dimethyl-pyrimidine-2,4,6-trione
Evipan
Hexobarbital
Hexobarbitone
Methexenyl
Methylhexabital
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EvipalNot Available
EvipanNot Available
TobinalNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Hexobarbital sodium
ThumbNot applicableDBSALT000914
Categories
UNIIAL8Z8K3P6S
CAS number56-29-1
WeightAverage: 236.267
Monoisotopic: 236.116092388
Chemical FormulaC12H16N2O3
InChI KeyInChIKey=UYXAWHWODHRRMR-UHFFFAOYSA-N
InChI
InChI=1S/C12H16N2O3/c1-12(8-6-4-3-5-7-8)9(15)13-11(17)14(2)10(12)16/h6H,3-5,7H2,1-2H3,(H,13,15,17)
IUPAC Name
5-(cyclohex-1-en-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione
SMILES
CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • 1,3-diazinane
  • Urea
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli.
PharmacodynamicsHexobarbital is a barbiturate derivative having hypnotic and sedative effects. It was used in the 1940s-1950s as an agent for inducing anesthesia for surgery and has a relatively fast onset of effects and short duration of action. However it can be difficult to control the depth of anesthesia with hexobarbital which makes it quite dangerous, and it has now been replaced by safer drugs in human medicine, usually thiopental would be the barbiturate of choice for this application these days.
Mechanism of actionHexobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABA-A receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding25%
Metabolism

Hepatic.

SubstrateEnzymesProduct
Hexobarbital
3'-HydroxyhexobarbitalDetails
Hexobarbital
Epoxy-hexobarbitalDetails
3'-Hydroxyhexobarbital
Not Available
3'-OxohexobarbitalDetails
3'-Oxohexobarbital
Not Available
Hexobarbital glutathione conjugate derivativeDetails
Epoxy-hexobarbital
Not Available
Hexobarbital dihydrodiol derivativeDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9793
Blood Brain Barrier+0.9649
Caco-2 permeable+0.519
P-glycoprotein substrateSubstrate0.5562
P-glycoprotein inhibitor IInhibitor0.7705
P-glycoprotein inhibitor IINon-inhibitor0.8379
Renal organic cation transporterNon-inhibitor0.7687
CYP450 2C9 substrateNon-substrate0.7622
CYP450 2D6 substrateNon-substrate0.894
CYP450 3A4 substrateNon-substrate0.543
CYP450 1A2 substrateNon-inhibitor0.7994
CYP450 2C9 inhibitorInhibitor0.5316
CYP450 2D6 inhibitorNon-inhibitor0.9369
CYP450 2C19 inhibitorNon-inhibitor0.6349
CYP450 3A4 inhibitorNon-inhibitor0.9571
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8803
Ames testNon AMES toxic0.7061
CarcinogenicityNon-carcinogens0.8753
BiodegradationNot ready biodegradable0.9143
Rat acute toxicity2.5050 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9348
hERG inhibition (predictor II)Non-inhibitor0.8502
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point146.5 °CPhysProp
water solubility435 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.98SANGSTER (1994)
logS-2.74ADME Research, USCD
pKa8.2SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility1.51 mg/mLALOGPS
logP1.8ALOGPS
logP1.25ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)8.41ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area66.48 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity61.95 m3·mol-1ChemAxon
Polarizability24.14 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.16 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-05cu-9310000000-eeec363075c613d35696View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis ReferenceNot Available
General References
  1. Takenoshita R, Toki S: [New aspects of hexobarbital metabolism: stereoselective metabolism, new metabolic pathway via GSH conjugation, and 3-hydroxyhexobarbital dehydrogenases]. Yakugaku Zasshi. 2004 Dec;124(12):857-71. [PubMed:15577260 ]
  2. Wahlstrom G: A study of the duration of acute tolerance induced with hexobarbital in male rats. Pharmacol Biochem Behav. 1998 Apr;59(4):945-8. [PubMed:9586853 ]
  3. Korkmaz S, Ljungblad E, Wahlstrom G: Interaction between flumazenil and the anesthetic effects of hexobarbital in the rat. Brain Res. 1995 Apr 10;676(2):371-7. [PubMed:7614008 ]
  4. Dall V, Orntoft U, Schmidt A, Nordholm L: Interaction of the competitive AMPA receptor antagonist NBQX with hexobarbital. Pharmacol Biochem Behav. 1993 Sep;46(1):73-6. [PubMed:8255925 ]
External Links
ATC CodesN01AF02N05CA16
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Hexobarbital is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Hexobarbital can be increased when it is combined with Abiraterone.
AcebutololHexobarbital may increase the hypotensive activities of Acebutolol.
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Hexobarbital.
AcepromazineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Hexobarbital.
AcetazolamideHexobarbital may increase the hypotensive activities of Acetazolamide.
adipiplonThe risk or severity of adverse effects can be increased when Hexobarbital is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Agomelatine.
AldesleukinHexobarbital may increase the hypotensive activities of Aldesleukin.
AlfaxaloneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Hexobarbital.
AliskirenHexobarbital may increase the hypotensive activities of Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Hexobarbital.
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Hexobarbital.
AmilorideHexobarbital may increase the hypotensive activities of Amiloride.
AmineptineThe metabolism of Amineptine can be increased when combined with Hexobarbital.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Hexobarbital.
AmiodaroneThe metabolism of Hexobarbital can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Amitriptyline.
AmlodipineHexobarbital may increase the hypotensive activities of Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Hexobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Amperozide.
AmrinoneThe metabolism of Amrinone can be increased when combined with Hexobarbital.
Amyl NitriteHexobarbital may increase the hypotensive activities of Amyl Nitrite.
ApraclonidineHexobarbital may increase the hypotensive activities of Apraclonidine.
AprepitantThe serum concentration of Hexobarbital can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Hexobarbital.
ArmodafinilThe metabolism of Hexobarbital can be decreased when combined with Armodafinil.
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Hexobarbital.
ArticaineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Asenapine.
AtazanavirThe metabolism of Hexobarbital can be decreased when combined with Atazanavir.
AtenololHexobarbital may increase the hypotensive activities of Atenolol.
AtomoxetineThe metabolism of Hexobarbital can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Azaperone.
AzelastineHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Hexobarbital.
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Hexobarbital.
Azilsartan medoxomilHexobarbital may increase the hypotensive activities of Azilsartan medoxomil.
AzimilideThe metabolism of Azimilide can be increased when combined with Hexobarbital.
AzithromycinThe metabolism of Hexobarbital can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Barbital.
BarnidipineThe metabolism of Barnidipine can be increased when combined with Hexobarbital.
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Hexobarbital.
BenazeprilHexobarbital may increase the hypotensive activities of Benazepril.
BendroflumethiazideHexobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.
BenidipineThe metabolism of Benidipine can be increased when combined with Hexobarbital.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Hexobarbital.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Benzyl alcohol.
BepridilThe metabolism of Bepridil can be increased when combined with Hexobarbital.
BetaxololHexobarbital may increase the hypotensive activities of Betaxolol.
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Hexobarbital.
BexaroteneThe serum concentration of Hexobarbital can be decreased when it is combined with Bexarotene.
BisoprololHexobarbital may increase the hypotensive activities of Bisoprolol.
BoceprevirThe metabolism of Hexobarbital can be decreased when combined with Boceprevir.
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Hexobarbital.
BortezomibThe metabolism of Hexobarbital can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Hexobarbital can be decreased when it is combined with Bosentan.
BretyliumHexobarbital may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.
BrimonidineHexobarbital may increase the hypotensive activities of Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Brotizolam.
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Hexobarbital.
BumetanideHexobarbital may increase the hypotensive activities of Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Hexobarbital.
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Hexobarbital.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Hexobarbital.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Hexobarbital.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Hexobarbital.
ButacaineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Hexobarbital.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Hexobarbital.
CaffeineThe metabolism of Hexobarbital can be decreased when combined with Caffeine.
CanagliflozinHexobarbital may increase the hypotensive activities of Canagliflozin.
CandesartanHexobarbital may increase the hypotensive activities of Candesartan.
CapecitabineThe metabolism of Hexobarbital can be decreased when combined with Capecitabine.
CaptoprilHexobarbital may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Hexobarbital.
CarbinoxamineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Carisoprodol.
CarteololHexobarbital may increase the hypotensive activities of Carteolol.
CarvedilolHexobarbital may increase the hypotensive activities of Carvedilol.
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Hexobarbital.
CeritinibThe serum concentration of Hexobarbital can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Hexobarbital can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Hexobarbital.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Hexobarbital.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Hexobarbital.
ChlorothiazideHexobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Hexobarbital.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Hexobarbital.
ChlorthalidoneHexobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Hexobarbital can be decreased when combined with Cholecalciferol.
CilazaprilHexobarbital may increase the hypotensive activities of Cilazapril.
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Hexobarbital.
CimetidineThe metabolism of Hexobarbital can be decreased when combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Hexobarbital.
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Hexobarbital.
CitalopramThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Citalopram.
CitalopramThe metabolism of Hexobarbital can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Hexobarbital can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Hexobarbital can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clemastine.
ClevidipineHexobarbital may increase the hypotensive activities of Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Hexobarbital is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clonazepam.
ClonidineHexobarbital may increase the hypotensive activities of Clonidine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Hexobarbital.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Hexobarbital.
ClotrimazoleThe metabolism of Hexobarbital can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Hexobarbital.
CobicistatThe metabolism of Hexobarbital can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Hexobarbital.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Hexobarbital.
ConivaptanThe serum concentration of Hexobarbital can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Hexobarbital can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Hexobarbital.
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Hexobarbital.
CyproheptadineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Hexobarbital can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Hexobarbital can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dantrolene.
DapagliflozinHexobarbital may increase the hypotensive activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Hexobarbital.
DapoxetineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dapoxetine.
DarodipineThe metabolism of Darodipine can be increased when combined with Hexobarbital.
DarunavirThe metabolism of Hexobarbital can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Hexobarbital can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Hexobarbital can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Hexobarbital can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Hexobarbital.
DesipramineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Detomidine.
DexamethasoneThe serum concentration of Hexobarbital can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dexbrompheniramine.
DexmedetomidineHexobarbital may increase the hypotensive activities of Dexmedetomidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hexobarbital.
DextromoramideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Hexobarbital.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Hexobarbital.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Hexobarbital.
DiclofenamideHexobarbital may increase the hypotensive activities of Diclofenamide.
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Hexobarbital.
DifenoxinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Hexobarbital can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dihydromorphine.
DiltiazemHexobarbital may increase the hypotensive activities of Diltiazem.
DiltiazemThe metabolism of Hexobarbital can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dimenhydrinate.
DinutuximabHexobarbital may increase the hypotensive activities of Dinutuximab.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Hexobarbital.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Hexobarbital.
DipyridamoleHexobarbital may increase the hypotensive activities of Dipyridamole.
DoramectinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Doramectin.
DosulepinThe metabolism of Dosulepin can be increased when combined with Hexobarbital.
DotarizineThe metabolism of Dotarizine can be increased when combined with Hexobarbital.
DoxazosinHexobarbital may increase the hypotensive activities of Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Doxepin.
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Hexobarbital.
DoxycyclineThe metabolism of Hexobarbital can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.
DoxylamineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Hexobarbital is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.
DronedaroneThe metabolism of Hexobarbital can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Hexobarbital.
DrotebanolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Hexobarbital.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Hexobarbital.
EcgonineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Hexobarbital is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Hexobarbital can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Efavirenz.
EfonidipineThe metabolism of Efonidipine can be increased when combined with Hexobarbital.
EmpagliflozinHexobarbital may increase the hypotensive activities of Empagliflozin.
EnalaprilHexobarbital may increase the hypotensive activities of Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Hexobarbital.
EntacaponeThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Entacapone.
EnzalutamideThe serum concentration of Hexobarbital can be decreased when it is combined with Enzalutamide.
EperisoneThe metabolism of Eperisone can be increased when combined with Hexobarbital.
EplerenoneHexobarbital may increase the hypotensive activities of Eplerenone.
EprosartanHexobarbital may increase the hypotensive activities of Eprosartan.
ErythromycinThe metabolism of Hexobarbital can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Hexobarbital can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Hexobarbital.
EsmololHexobarbital may increase the hypotensive activities of Esmolol.
EsomeprazoleThe metabolism of Hexobarbital can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Hexobarbital.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Hexobarbital.
Etacrynic acidHexobarbital may increase the hypotensive activities of Etacrynic acid.
EthanolHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Hexobarbital.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hexobarbital.
EthosuximideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethotoin.
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Hexobarbital.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Hexobarbital.
EtoperidoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Etorphine.
EtravirineThe serum concentration of Hexobarbital can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ezogabine.
FelbamateThe serum concentration of Hexobarbital can be increased when it is combined with Felbamate.
FelbamateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Felbamate.
FelodipineHexobarbital may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fencamfamine.
FendilineThe metabolism of Fendiline can be increased when combined with Hexobarbital.
FenfluramineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hexobarbital.
FexofenadineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Flibanserin.
FloxuridineThe metabolism of Hexobarbital can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Hexobarbital can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fludiazepam.
FlunarizineThe metabolism of Flunarizine can be increased when combined with Hexobarbital.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Hexobarbital.
FlunitrazepamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Flunitrazepam.
FluorouracilThe metabolism of Hexobarbital can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fluoxetine.
FluoxetineThe metabolism of Hexobarbital can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Hexobarbital.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Hexobarbital.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Hexobarbital.
FluspirileneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Hexobarbital can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fluvoxamine.
FluvoxamineThe metabolism of Hexobarbital can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Hexobarbital can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Hexobarbital can be increased when it is combined with Fosaprepitant.
FosinoprilHexobarbital may increase the hypotensive activities of Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fospropofol.
FurosemideHexobarbital may increase the hypotensive activities of Furosemide.
Fusidic AcidThe serum concentration of Hexobarbital can be increased when it is combined with Fusidic Acid.
GabapentinThe metabolism of Gabapentin can be increased when combined with Hexobarbital.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Hexobarbital.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Hexobarbital is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Gamma Hydroxybutyric Acid.
GemfibrozilThe metabolism of Hexobarbital can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Glutethimide.
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Hexobarbital.
GuanfacineHexobarbital may increase the hypotensive activities of Guanfacine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Hexobarbital.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Hexobarbital.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Hexobarbital.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Hexobarbital.
HeroinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Heroin.
HydralazineHexobarbital may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideHexobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Hexobarbital.
HydroflumethiazideHexobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Hexobarbital.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.
HydroxyzineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Hydroxyzine.
IdelalisibThe serum concentration of Hexobarbital can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Iloperidone.
ImatinibThe metabolism of Hexobarbital can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Indalpine.
IndapamideHexobarbital may increase the orthostatic hypotensive activities of Indapamide.
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Hexobarbital.
IndinavirThe metabolism of Hexobarbital can be decreased when combined with Indinavir.
IrbesartanHexobarbital may increase the hypotensive activities of Irbesartan.
IrbesartanThe metabolism of Hexobarbital can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Hexobarbital can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Hexobarbital.
IsoniazidThe metabolism of Hexobarbital can be decreased when combined with Isoniazid.
Isosorbide DinitrateHexobarbital may increase the hypotensive activities of Isosorbide Dinitrate.
Isosorbide MononitrateHexobarbital may increase the hypotensive activities of Isosorbide Mononitrate.
IsoxsuprineHexobarbital may increase the hypotensive activities of Isoxsuprine.
IsradipineHexobarbital may increase the hypotensive activities of Isradipine.
IsradipineThe metabolism of Hexobarbital can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Hexobarbital can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Hexobarbital can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Hexobarbital.
KetazolamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ketobemidone.
KetoconazoleThe metabolism of Hexobarbital can be decreased when combined with Ketoconazole.
LabetalolHexobarbital may increase the hypotensive activities of Labetalol.
LacidipineThe metabolism of Lacidipine can be increased when combined with Hexobarbital.
LamotrigineThe metabolism of Lamotrigine can be increased when combined with Hexobarbital.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Hexobarbital.
LeflunomideThe metabolism of Hexobarbital can be decreased when combined with Leflunomide.
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Hexobarbital.
LevetiracetamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Levetiracetam.
LevobunololHexobarbital may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Hexobarbital.
LevocabastineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Hexobarbital.
LevomilnacipranThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Hexobarbital.
LidocaineThe metabolism of Hexobarbital can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Lidocaine.
LisinoprilHexobarbital may increase the hypotensive activities of Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Lofentanil.
LopinavirThe metabolism of Hexobarbital can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Hexobarbital.
LosartanHexobarbital may increase the hypotensive activities of Losartan.
LosartanThe metabolism of Hexobarbital can be decreased when combined with Losartan.
LovastatinThe metabolism of Hexobarbital can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Hexobarbital.
Lu AA21004The risk or severity of adverse effects can be increased when Hexobarbital is combined with Lu AA21004.
LuliconazoleThe serum concentration of Hexobarbital can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Hexobarbital can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.
Magnesium SulfateThe metabolism of Magnesium Sulfate can be increased when combined with Hexobarbital.
ManidipineThe metabolism of Manidipine can be increased when combined with Hexobarbital.
MannitolHexobarbital may increase the hypotensive activities of Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Maprotiline.
MecamylamineHexobarbital may increase the hypotensive activities of Mecamylamine.
MeclizineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Hexobarbital.
MelperoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Hexobarbital.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Hexobarbital.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Hexobarbital.
MetaxaloneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Hexobarbital.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methaqualone.
MethazolamideHexobarbital may increase the hypotensive activities of Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Hexobarbital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Hexobarbital.
MethsuximideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methsuximide.
MethyclothiazideHexobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
MethyldopaHexobarbital may increase the hypotensive activities of Methyldopa.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Hexobarbital.
MetipranololHexobarbital may increase the hypotensive activities of Metipranolol.
MetolazoneHexobarbital may increase the orthostatic hypotensive activities of Metolazone.
MetoprololHexobarbital may increase the hypotensive activities of Metoprolol.
MetyrosineHexobarbital may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Hexobarbital can be decreased when combined with Mexiletine.
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.
MibefradilThe metabolism of Mibefradil can be increased when combined with Hexobarbital.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Hexobarbital.
MifepristoneThe metabolism of Hexobarbital can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.
MinoxidilHexobarbital may increase the hypotensive activities of Minoxidil.
MirtazapineHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Hexobarbital.
MitotaneThe serum concentration of Hexobarbital can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Hexobarbital can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Hexobarbital can be decreased when it is combined with Modafinil.
MoexiprilHexobarbital may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Hexobarbital.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.
NabiloneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Nabilone.
NadololHexobarbital may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Hexobarbital can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Hexobarbital.
NebivololHexobarbital may increase the hypotensive activities of Nebivolol.
NefazodoneThe metabolism of Hexobarbital can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Hexobarbital can be decreased when combined with Nelfinavir.
NesiritideHexobarbital may increase the hypotensive activities of Nesiritide.
NetupitantThe serum concentration of Hexobarbital can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Hexobarbital can be decreased when combined with Nevirapine.
NicardipineHexobarbital may increase the hypotensive activities of Nicardipine.
NicardipineThe metabolism of Hexobarbital can be decreased when combined with Nicardipine.
NifedipineHexobarbital may increase the hypotensive activities of Nifedipine.
NiguldipineThe metabolism of Niguldipine can be increased when combined with Hexobarbital.
NilotinibThe metabolism of Hexobarbital can be decreased when combined with Nilotinib.
NiludipineThe metabolism of Niludipine can be increased when combined with Hexobarbital.
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Hexobarbital.
NimesulideThe metabolism of Nimesulide can be increased when combined with Hexobarbital.
NimodipineHexobarbital may increase the hypotensive activities of Nimodipine.
NisoldipineHexobarbital may increase the hypotensive activities of Nisoldipine.
NitrazepamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Hexobarbital.
NitroglycerinHexobarbital may increase the hypotensive activities of Nitroglycerin.
NitroprussideHexobarbital may increase the hypotensive activities of Nitroprusside.
Nitrous oxideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Olanzapine.
OlaparibThe metabolism of Hexobarbital can be decreased when combined with Olaparib.
OlmesartanHexobarbital may increase the hypotensive activities of Olmesartan.
OlopatadineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Olopatadine.
OmeprazoleThe metabolism of Hexobarbital can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Hexobarbital.
OpiumThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Opium.
OrphenadrineHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Hexobarbital.
OsanetantThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Osanetant.
OsimertinibThe serum concentration of Hexobarbital can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Hexobarbital.
OxprenololThe serum concentration of Oxprenolol can be decreased when it is combined with Hexobarbital.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Hexobarbital.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Hexobarbital.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hexobarbital.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Hexobarbital.
PalbociclibThe serum concentration of Hexobarbital can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Hexobarbital.
PantoprazoleThe metabolism of Hexobarbital can be decreased when combined with Pantoprazole.
PapaverineHexobarbital may increase the hypotensive activities of Papaverine.
ParaldehydeHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Hexobarbital.
ParoxetineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Hexobarbital can be increased when it is combined with Peginterferon alfa-2b.
PenbutololHexobarbital may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hexobarbital.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Hexobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Perampanel.
PerhexilineThe metabolism of Perhexiline can be increased when combined with Hexobarbital.
PerindoprilHexobarbital may increase the hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Hexobarbital.
PethidineHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Hexobarbital.
PhenindioneThe metabolism of Phenindione can be increased when combined with Hexobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Hexobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Phenoxyethanol.
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Hexobarbital.
PhenytoinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Hexobarbital.
PinaveriumThe metabolism of Pinaverium can be increased when combined with Hexobarbital.
PindololHexobarbital may increase the hypotensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pizotifen.
PolythiazideHexobarbital may increase the orthostatic hypotensive activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pomalidomide.
PosaconazoleThe metabolism of Hexobarbital can be decreased when combined with Posaconazole.
PractololThe serum concentration of Practolol can be decreased when it is combined with Hexobarbital.
PramipexoleHexobarbital may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Prazepam.
PrazosinHexobarbital may increase the hypotensive activities of Prazosin.
PregabalinThe metabolism of Pregabalin can be increased when combined with Hexobarbital.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Hexobarbital.
PrenylamineThe metabolism of Prenylamine can be increased when combined with Hexobarbital.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Hexobarbital.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Hexobarbital.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Hexobarbital.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Hexobarbital.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Hexobarbital.
PromethazineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Promethazine.
PropacetamolThe metabolism of Propacetamol can be increased when combined with Hexobarbital.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Hexobarbital.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Hexobarbital.
PropoxycaineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Propoxycaine.
PropranololHexobarbital may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Hexobarbital is combined with PSD502.
PyridoxineThe metabolism of Hexobarbital can be increased when combined with Pyridoxine.
PyrimethamineThe metabolism of Hexobarbital can be decreased when combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Quazepam.
QuetiapineHexobarbital may increase the hypotensive activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Hexobarbital.
QuinaprilHexobarbital may increase the hypotensive activities of Quinapril.
QuinethazoneHexobarbital may increase the orthostatic hypotensive activities of Quinethazone.
QuinineThe metabolism of Hexobarbital can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ramelteon.
RamiprilHexobarbital may increase the hypotensive activities of Ramipril.
RanolazineThe metabolism of Hexobarbital can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hexobarbital.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Hexobarbital.
ReserpineHexobarbital may increase the hypotensive activities of Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Hexobarbital.
RifabutinThe metabolism of Hexobarbital can be increased when combined with Rifabutin.
RifampicinThe metabolism of Hexobarbital can be increased when combined with Rifampicin.
RifapentineThe metabolism of Hexobarbital can be increased when combined with Rifapentine.
RiociguatHexobarbital may increase the hypotensive activities of Riociguat.
RisedronateThe metabolism of Risedronate can be increased when combined with Hexobarbital.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Hexobarbital.
RitonavirThe metabolism of Hexobarbital can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Romifidine.
RopiniroleHexobarbital may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Hexobarbital can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Hexobarbital.
RotigotineHexobarbital may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Hexobarbital.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Hexobarbital is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Hexobarbital can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Hexobarbital.
SertindoleThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Sertraline.
SertralineThe metabolism of Hexobarbital can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Hexobarbital.
SildenafilThe metabolism of Hexobarbital can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Hexobarbital can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Hexobarbital can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Sodium oxybate.
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Hexobarbital.
SorafenibThe metabolism of Hexobarbital can be decreased when combined with Sorafenib.
SotalolHexobarbital may increase the hypotensive activities of Sotalol.
SpironolactoneHexobarbital may increase the hypotensive activities of Spironolactone.
St. John's WortThe serum concentration of Hexobarbital can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hexobarbital.
SulfadiazineThe metabolism of Hexobarbital can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Hexobarbital can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Hexobarbital can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Hexobarbital.
SuvorexantThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tasimelteon.
TelaprevirThe metabolism of Hexobarbital can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Hexobarbital can be decreased when combined with Telithromycin.
TelmisartanHexobarbital may increase the hypotensive activities of Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Hexobarbital.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Hexobarbital.
TenofovirThe metabolism of Hexobarbital can be decreased when combined with Tenofovir.
TerazosinHexobarbital may increase the hypotensive activities of Terazosin.
TeriflunomideThe serum concentration of Hexobarbital can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tetrodotoxin.
ThalidomideHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Hexobarbital.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Hexobarbital.
TheophyllineThe metabolism of Hexobarbital can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Hexobarbital.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Hexobarbital.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Hexobarbital.
ThiothixeneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tiagabine.
TianeptineThe metabolism of Tianeptine can be increased when combined with Hexobarbital.
TicagrelorThe metabolism of Hexobarbital can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Hexobarbital can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tiletamine.
TimololHexobarbital may increase the hypotensive activities of Timolol.
TizanidineHexobarbital may increase the hypotensive activities of Tizanidine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Hexobarbital.
TocilizumabThe serum concentration of Hexobarbital can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Hexobarbital can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tolcapone.
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Hexobarbital.
TopiramateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Topiramate.
TorasemideHexobarbital may increase the hypotensive activities of Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Hexobarbital.
TrandolaprilHexobarbital may increase the hypotensive activities of Trandolapril.
TranilastThe metabolism of Tranilast can be increased when combined with Hexobarbital.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hexobarbital.
TrazodoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Trazodone.
TriamtereneHexobarbital may increase the hypotensive activities of Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Hexobarbital.
TrichlormethiazideHexobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Hexobarbital.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Hexobarbital.
TrimethoprimThe metabolism of Hexobarbital can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Triprolidine.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Hexobarbital.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Hexobarbital.
ValsartanHexobarbital may increase the hypotensive activities of Valsartan.
ValsartanThe metabolism of Hexobarbital can be decreased when combined with Valsartan.
VemurafenibThe serum concentration of Hexobarbital can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Hexobarbital can be decreased when combined with Venlafaxine.
VerapamilHexobarbital may increase the hypotensive activities of Verapamil.
VerapamilThe metabolism of Hexobarbital can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Vilazodone.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Hexobarbital.
VoriconazoleThe metabolism of Hexobarbital can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Vortioxetine.
WarfarinThe metabolism of Warfarin can be increased when combined with Hexobarbital.
XylazineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Xylazine.
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Hexobarbital.
ZafirlukastThe metabolism of Hexobarbital can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Hexobarbital.
ZiconotideThe metabolism of Ziconotide can be increased when combined with Hexobarbital.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Hexobarbital.
ZimelidineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Zimelidine.
ZiprasidoneThe metabolism of Hexobarbital can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Hexobarbital.
ZonisamideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Hexobarbital.
ZotepineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
  5. Tomlin SL, Jenkins A, Lieb WR, Franks NP: Preparation of barbiturate optical isomers and their effects on GABA(A) receptors. Anesthesiology. 1999 Jun;90(6):1714-22. [PubMed:10360871 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  8. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ionotropic glutamate receptor activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA2
Uniprot ID:
P42262
Molecular Weight:
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Kainate selective glutamate receptor activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK2
Uniprot ID:
Q13002
Molecular Weight:
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Adedoyin A, Prakash C, O'Shea D, Blair IA, Wilkinson GR: Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics. 1994 Feb;4(1):27-38. [PubMed:8004130 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Lewis DF, Modi S, Dickins M: Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82. [PubMed:11996013 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M: Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica. 1996 Jul;26(7):681-93. [PubMed:8819299 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23